Reinfection with SARS-CoV-2: Implications for Vaccines

@article{Cohen2020ReinfectionWS,
  title={Reinfection with SARS-CoV-2: Implications for Vaccines},
  author={Jeffrey I. Cohen and Peter D. Burbelo},
  journal={Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America},
  year={2020}
}
  • J. CohenP. Burbelo
  • Published 18 December 2020
  • Medicine, Biology
  • Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
Abstract Infection with SARS-CoV-2 has become pandemic and the duration of protective immunity to the virus is unknown. Cases of persons reinfected with the virus are being reported with increasing frequency. At present it is unclear how common reinfection with SARS-CoV-2 is and how long serum antibodies and virus-specific T cells persist after infection. For many other respiratory virus infections, including influenza and the seasonal coronaviruses that cause colds, serum antibodies persist… 

Tables from this paper

An immune correlate of SARS-CoV-2 infection and severity of reinfections

Prior infection-induced immunity is protective against infection when predominantly gamma and delta SARS-CoV-2 circulated, and the protective antibody titers presented may be useful for vaccine policy and control measures.

COVID-19 Vaccine: Between Myth and Truth

The FDA- and/or EMA-authorized vaccines that are mostly based on mRNA or viral vector platforms are discussed, debunk false myths about the COVID-19 vaccine as well as discuss the impact of viral variants and the possible future developments.

The protective immunity induced by SARS-CoV-2 infection and vaccination: a critical appraisal

The present essay discusses issues based on current immunological concepts to get rid of the outdated notion of a naïve, static, and closed immune system and shed light on the features and mechanisms of the protective immunity elicited by SARS-CoV-2 infection and vaccines.

Natural immunity to SARS-CoV-2 and breakthrough infections in vaccinated and unvaccinated patients with cancer

This study shows that reinfections in COVID-19 survivors with cancer are possible and more common in patients with haematological malignancies, highlighting the importance of universal vaccination of patients with cancer.

SARS-CoV-2 Reinfection Is a New Challenge for the Effectiveness of Global Vaccination Campaign: A Systematic Review of Cases Reported in Literature

It is evident that the level of immunity is not 100% for all individuals and how it is necessary to continue to observe all the prescriptions recently indicated in the literature in order to avoid new contagion for all people after healing from COVID-19 or becoming asymptomatic positive.

Serological Evidence for Reinfection with SARS-CoV-2; An Observational Cohort Study

IgG concentration and avidity can be used as an additional diagnostic marker to confirm reinfection with SARS-Cov-2 and are expected to clear the infection more effectively, thereby reducing contagiousness and clinical severity.

Nasal Nanovaccines for SARS-CoV-2 to Address COVID-19

Nasal nanovaccines are easy to use, safe, multifunctional, and can be distributed quickly, demonstrating strong prospects as a vaccination method for SARS-CoV-2, Sars-Cov-2 variants, or SARS/SARS-coV-n.

Epidemiological assessment of SARS-CoV-2 reinfection

Effectiveness Associated With Vaccination After COVID-19 Recovery in Preventing Reinfection

It is suggested that among people who have recovered from COVID-19, subsequent completion of the primary vaccination series reduced the risk of reinfection by approximately half.

Severe Acute Respiratory Syndrome Coronavirus 2 Reinfection Cases Corroborated by Sequencing

Evaluating cases of reinfection may offer some insight into areas for further investigation regarding durability of immune response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), but analysis is limited by the heterogeneous methods used among reports.
...

References

SHOWING 1-10 OF 50 REFERENCES

Robust neutralizing antibodies to SARS-CoV-2 infection persist for months

The vast majority of infected individuals with mild-to-moderate COVID-19 experience robust immunoglobulin G antibody responses against the viral spike protein, and titers are relatively stable for at least a period of about 5 months and that anti-spike binding titers significantly correlate with neutralization of authentic SARS-CoV-2.

Antibodies to SARS-CoV-2 are associated with protection against reinfection

Positive baseline anti-spike antibodies were associated with lower rates of PCR-positivity (with or without symptoms) and further work is required to determine the long-term duration and correlates of post-infection immunity.

Lack of cross-neutralization by SARS patient sera towards SARS-CoV-2

It is demonstrated that there is no detectable cross-neutralization by SARS patient sera against SARS-CoV-2, and there are significant levels of neutralizing antibodies in recovered SARS patients 9–17 years after initial infection.

Humoral Immune Response to SARS-CoV-2 in Iceland

The authors' results indicate that antiviral antibodies against SARS-CoV-2 did not decline within 4 months after diagnosis, and antiviral antibody titers assayed by two pan-Ig assays remained on a plateau for the remainder of the study.

Correlates of Protection Against SARS-CoV-2 in Rhesus Macaques

It is demonstrated that relatively low antibody titers are sufficient for protection against SARS-CoV-2 in rhesus macaques, and that cellular immune responses may also contribute to protection if antibody responses are suboptimal.

Immunity to and frequency of reinfection with respiratory syncytial virus.

It is suggested that humoral neutralizing, F, and G antibodies correlate with resistance to reinfection, but protection is far from complete and is of short duration.

Neutralizing Antibodies Correlate with Protection from SARS-CoV-2 in Humans during a Fishery Vessel Outbreak with a High Attack Rate

The development of vaccines against SARS-CoV-2 would be greatly facilitated by the identification of immunological correlates of protection in humans, as the presence of neutralizing antibodies from prior infection was significantly associated with protection against reinfection.

Influenza A Reinfection in Sequential Human Challenge: Implications for Protective Immunity and "Universal" Vaccine Development.

  • M. MemoliA. Han J. Taubenberger
  • Medicine
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • 2019
It is demonstrated that sequential infection with the identical influenza A virus can occur and suggest it may not be rare and these data raise questions about immune memory responses in an acute superficial respiratory mucosal infection and their implications in development of broadly protective influenza vaccines.

COVID-19 re-infection by a phylogenetically distinct SARS-coronavirus-2 strain confirmed by whole genome sequencing

  • K. ToI. Hung K. Yuen
  • Biology, Medicine
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • 2020
The results suggest SARS-CoV-2 may continue to circulate among the human populations despite herd immunity due to natural infection or vaccination, and further studies of patients with re-infection will shed light on protective correlates important for vaccine design.

Immunological memory to SARS-CoV-2 assessed for up to eight months after infection

It is observed that each component of SARS-CoV-2 immune memory exhibited distinct kinetics, and Spike IgG was relatively stable over 6+ months.